Credit Analysis: Morningside Pharmaceuticals Limited

1. Credit Opinion: APPROVE

Rationale: Morningside Pharmaceuticals presents a strong credit profile underpinned by a robust and rapidly improving balance sheet, consistent turnover growth, and the financial backing of H.I.G Capital through the Aspire Group structure. The company operates in a defensive sector with NHS as its primary customer base, has maintained zero bad debts for two consecutive years, and has demonstrated significant deleveraging over the review period. The declining cash position warrants monitoring but appears to be a strategic deployment toward infrastructure investment and supply chain resilience rather than operational distress.

2. Financial Strength

Balance Sheet Summary:

Key Observations:

• Exceptional deleveraging trajectory: Total liabilities have reduced by £15.6m over two years (from £28.8m to £13.2m), representing a 54% reduction. This indicates either active debt repayment or strong profit retention, both positive credit indicators.

• Strong equity position: Net assets of £37.2m against total liabilities of £13.2m yields a debt-to-equity ratio of approximately 0.35:1, which is conservative by sector standards. The balance sheet provides substantial cushion for creditors.

• Asset growth: Total assets have grown by 22% over two years, consistent with the reported turnover increase from £79.4m to £84.0m (5.8% growth in 2024).

• Capital base: Share capital remains minimal at £100, with the majority of shareholders' funds derived from retained profits (£37.1m in P&L reserve), demonstrating the business's self-sustaining earnings capacity.

Concern: The PSC register shows two entities (Remedi Medical Holdings Limited and Randalsun Capital Limited) both owning >75% of shares and voting rights. This overlapping declaration requires clarification to understand the true control structure, particularly regarding any intercompany obligations or guarantees that may not be visible on these standalone accounts.

3. Cash Flow Assessment

Liquidity Position:

• Cash decline of £4.3m year-on-year requires examination. The strategic report indicates this is attributable to:
• Significant investment in infrastructure and capabilities to accommodate group expansion
• Deliberate elevation of stock levels to mitigate supply chain risk

• Continued debt reduction

• Working capital context: The company reports maintaining higher stock levels throughout 2024 as a deliberate strategy. For a pharmaceutical wholesaler with £84m turnover, a cash balance of £1.4m represents approximately 6 days of revenue, which is tight but potentially sustainable given the nature of NHS receivables (reliable government payer).

• Credit risk profile: Zero bad debts in both 2023 and 2024 is exceptional and indicates strong credit control processes and a high-quality customer base.

• No forward exchange contracts: The company carries unhedged foreign exchange exposure, primarily against the Euro. While noted as a risk, the absence of hedging instruments also means no contingent liabilities from derivative positions.

Assessment: The cash position is the primary vulnerability in the credit profile. However, the context suggests this is a temporary deployment of capital rather than structural underperformance. The company's ability to reduce liabilities by £7.5m whilst growing assets by £1.9m and investing in infrastructure indicates strong operational cash generation.

4. Monitoring Points